Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.
作者信息
Meier J, Nüesch E
出版信息
Br J Clin Pharmacol. 1977 Jun;4(3):371-2. doi: 10.1111/j.1365-2125.1977.tb00726.x.
Abstract
摘要
相似文献
1
Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.吲哚洛尔，一种首过效应可忽略不计的β肾上腺素受体阻滞剂。
Br J Clin Pharmacol. 1977 Jun;4(3):371-2. doi: 10.1111/j.1365-2125.1977.tb00726.x.
2
First-pass effect of the beta-adrenoceptor blocking agent pindolol in the dog [proceedings].β-肾上腺素能阻滞剂吲哚洛尔在犬体内的首过效应[会议论文集]
Br J Pharmacol. 1977 Mar;59(3):492P.
3
Pharmacokinetics of a new beta-adrenoceptor blocking agent, LF 17-895, in man.新型β-肾上腺素受体阻滞剂LF 17-895在人体中的药代动力学
Arzneimittelforschung. 1975 Jul;25(7):1067-72.
4
Study of the bioavailability of pindolol in malabsorption syndromes.吲哚洛尔在吸收不良综合征中的生物利用度研究。
Br J Clin Pharmacol. 1984 Oct;18(4):632-7. doi: 10.1111/j.1365-2125.1984.tb02518.x.
5
Pindolol availability in hypertensive patients with normal and impaired renal function.正常肾功能和肾功能受损的高血压患者中吲哚洛尔的可利用性。
Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):505-10. doi: 10.1002/cpt1977225part1505.
6
[Clinicopharmacological studies with pindolol following intravenous and oral administration].
Adv Clin Pharmacol. 1976;11:9-13.
7
Pharmacokinetics and pharmacodynamics of mepindolol sulphate.硫酸美吲哚洛尔的药代动力学与药效学
Int J Clin Pharmacol Ther Toxicol. 1980 Apr;18(4):169-76.
8
Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.高血压患者在肾功能正常和受损情况下吲哚洛尔的药代动力学及肝脏摄取率
J Clin Pharmacol. 1977 Aug-Sep;17(8-9):501-8. doi: 10.1002/j.1552-4604.1977.tb05643.x.
9
10
[Evaluation of pindolol absorption in malabsorption syndromes].[匹吲哚洛尔在吸收不良综合征中的吸收评估]
Gastroenterol Clin Biol. 1983 Apr;7(4):398-404.
引用本文的文献
1
Changes of Drug Pharmacokinetics in Patients with Short Bowel Syndrome: A Systematic Review.短肠综合征患者药物药代动力学的变化：系统评价。
Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):465-478. doi: 10.1007/s13318-021-00696-y. Epub 2021 Jul 1.
2
Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds.确定危重症患者肾脏药物清除增加的潜在机制：外源性标记化合物的应用。
Crit Care. 2014 Nov 29;18(6):657. doi: 10.1186/s13054-014-0657-z.
3
A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet.20毫克缓释吲哚洛尔与普通片剂的药效学和药代动力学比较。
Eur J Clin Pharmacol. 1981;20(3):179-83. doi: 10.1007/BF00544595.
4
Metabolism of pindolol in patients with renal failure.肾衰竭患者中吲哚洛尔的代谢
Eur J Clin Pharmacol. 1982;22(5):423-8. doi: 10.1007/BF00542547.
5
Elimination of pindolol in liver disease.肝病患者中吲哚洛尔的消除情况。
Eur J Clin Pharmacol. 1982;22(3):247-51. doi: 10.1007/BF00545223.
6
Effects of age and smoking on the pharmacokinetics of pindolol and propranolol.年龄和吸烟对吲哚洛尔及普萘洛尔药代动力学的影响。
Br J Clin Pharmacol. 1982;13(Suppl 2):217S-222S. doi: 10.1111/j.1365-2125.1982.tb01914.x.
7
Cardiac dose-response relationships of oral and intravenous pindolol.口服和静脉注射吲哚洛尔的心脏剂量-反应关系。
Br J Clin Pharmacol. 1982;13(Suppl 2):193S-198S. doi: 10.1111/j.1365-2125.1982.tb01910.x.
8
A standard approach to compiling clinical pharmacokinetic data.一种汇编临床药代动力学数据的标准方法。
J Pharmacokinet Biopharm. 1981 Feb;9(1):59-127. doi: 10.1007/BF01059343.
9
Study of the bioavailability of pindolol in malabsorption syndromes.吲哚洛尔在吸收不良综合征中的生物利用度研究。
Br J Clin Pharmacol. 1984 Oct;18(4):632-7. doi: 10.1111/j.1365-2125.1984.tb02518.x.
10
Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.吲哚洛尔——一种具有部分激动剂活性的β-肾上腺素能受体阻滞剂：临床药理学考量
Br J Clin Pharmacol. 1982;13(Suppl 2):187S-192S. doi: 10.1111/j.1365-2125.1982.tb01909.x.
本文引用的文献
1
Influence of first-pass effect on availability of drugs on oral administration.首过效应对口服给药时药物可利用度的影响。
J Pharm Sci. 1971 Sep;60(9):1338-40. doi: 10.1002/jps.2600600909.
2
The disposition of propranolol. I. Elimination during oral absorption in man.普萘洛尔的处置。I. 人体口服吸收过程中的消除
Pharmacology. 1972;7(3):159-68. doi: 10.1159/000136285.
3
Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia.未标记和14C标记的吲哚洛尔在尿毒症中的药代动力学。
Eur J Clin Pharmacol. 1974;7(1):25-9. doi: 10.1007/BF00614386.
4
Pharmacokinetics of pindolol in man.吲哚洛尔在人体中的药代动力学。
Eur J Clin Pharmacol. 1974;7(1):17-24. doi: 10.1007/BF00614385.
5
A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.一种荧光法测定血浆和尿液中β受体阻滞剂4-(2-羟基-3-异丙氨基丙氧基)-吲哚(LB46)的方法。
Experientia. 1969 Aug 15;25(8):802-3. doi: 10.1007/BF01897885.
6
Proceedings: Biological and pharmacological myocardial elimination rate of propranolol.论文集：普萘洛尔的生物及药理心肌清除率
Br Heart J. 1975 May;37(5):555.
7
8
Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.肾上腺素能β1受体拮抗剂美托洛尔在人体中的药代动力学和药效学联合研究。
Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):31-44. doi: 10.1111/j.1600-0773.1975.tb03320.x.
9
beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.健康志愿者中吲哚洛尔和普萘洛尔的β-肾上腺素受体阻断活性及作用持续时间
Br J Clin Pharmacol. 1976 Apr;3(2):251-7. doi: 10.1111/j.1365-2125.1976.tb00600.x.
10
Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol.某些肾上腺素能β受体拮抗剂的药代动力学和生物药剂学，特别着重于阿普洛尔和美托洛尔。
Acta Pharmacol Toxicol (Copenh). 1975;37(1):1-39. doi: 10.1111/j.1600-0773.1975.tb03091.x.
Zotero 插件